At the news
? BULLISHIMPACT 7/10 8-K filed Jun 1, 2026 at 16:01 ET
Oruka Therapeutics amended its IL-23 license agreement with Paragon Therapeutics to expand the field of use to include inflammatory bowel disease (IBD), removing a key restriction on ORKA-001's addressable market. The amendment imposes dosing restrictions (no monotherapy IBD dosing until June 2030, no combination dosing until June 2028), but these accelerate to June 2028 upon a material transaction like a change of control. This significantly expands the commercial opportunity for ORKA-001, a $3.5B market cap biotech's lead asset.
- Oruka expanded the field of use for its IL-23 license to include all therapeutic areas, including inflammatory bowel disease (IBD), which was previously excluded.
- Monotherapy dosing of ORKA-001 for IBD is restricted until June 1, 2030; combination dosing until June 1, 2028.
- Upon a material transaction (change of control or sale of Phase II-stage assets), the monotherapy restriction accelerates to June 1, 2028.
- Paragon granted Oruka exclusivity in the IBD field until October 11, 2029, and Oruka granted Paragon a non-exclusive cross-license for retained antibodies outside IBD.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access